nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Drum drying is a method used for drying out liquids from raw materials with a drying drum. In the drum-drying process, pureed raw ingredients are dried at relatively low temperatures over rotating, high-capacity drums that produce sheets of drum-dried product. This product is milled to a finished flake or powder form. Modern drum drying techniques results in dried ingredients which reconstitute immediately and retain much of their original flavor, color and nutritional value. Some advantages of drum drying include the ability to dry viscous foods which cannot be easily dried with other methods. Drum dryers are easy to operate and maintain. Other products where drum drying can be used are, for example, starches, breakfast cereals, baby food, and instant mashed potatoes to make them cold-water-soluble.
Psychotria viridis (Chacruna) – leaves Psychotria carthagenensis (Amyruca) – leaves Diplopterys cabrerana (Chaliponga, Chagropanga, Banisteriopsis rusbyana) – leaves Mimosa tenuiflora (M. hostilis) - root bark Other common admixtures:
Some of the prosocial and antiaggressive effects of oxytocin may be mediated by vasopressin V1A receptor agonism rather than by oxytocin receptor agonism. Conversely, other studies have implicated oxytocin receptor agonism in these effects of oxytocin.
PLGA, PLG, or poly(lactic-co-glycolic) acid (CAS: 26780-50-7 ) is a biodegradable, biocompatible copolymer of lactic and glycolic acid used widely in biomedical devices and tissue-engineering materials approved by the Food and Drug Administration (FDA). PLGA is synthesized by means of ring-opening co-polymerization of two different monomers: glycolide and lactide, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid, respectively. The polymer has emerged as platform for advanced drug delivery systems, including nanoparticles, because of its tunable degradation behavior and ability to encapsulate different therapeutic agents. Recent research features its growing role in precision medicine and targeted therapies, specifically in cancer treatment and controlled release applications.
Sources: en.wikipedia.org
== Use and effects == Noribogaine is the major active metabolite of the oneirogen ibogaine and is thought to be primarily though not exclusively responsible for its effects. In contrast to ibogaine, noribogaine has been limitedly evaluated in humans. It was noted in 2007 that administration of noribogaine to humans had not yet been reported. In 2015 and 2016 however, two clinical studies of noribogaine were published. It was tested at relatively low doses of 3 to 180 mg in these studies. At these doses, no hallucinations, dream-like states, or other hallucinogenic effects were reported. Similarly, it produced no μ-opioid receptor agonistic pharmacodynamic effects, such as pupil constriction or analgesia. At higher doses, in the area of 400 to 1,000 mg or more, ibogaine has been reported to produce hallucinogenic effects.
An mRNA molecule is said to be monocistronic when it contains the genetic information to translate only a single protein chain (polypeptide). This is the case for most of the eukaryotic mRNAs. On the other hand, polycistronic mRNA carries several open reading frames (ORFs), each of which is translated into a polypeptide. These polypeptides usually have a related function (they often are the subunits composing a final complex protein) and their coding sequence is grouped and regulated together in a regulatory region, containing a promoter and an operator. Most of the mRNA found in bacteria and archaea is polycistronic, as is the human mitochondrial genome. Dicistronic or bicistronic mRNA encodes only two proteins.
Genetic factors, along with socio-environmental (e.g., psychosocial) factors, have been established as significant contributors to addiction vulnerability. Addiction is substantially heritable. Twin and adoption studies estimate the heritability of alcohol use disorder at approximately 50%, with comparable estimates across other substances. This risk is polygenic: it reflects the combined small effects of many common variants rather than any single gene. Genome-wide association studies (GWAS) are used to examine genetic associations with dependence, addiction, and drug use, and have begun to map this architecture, and distinguish loci associated with a broad general liability to addiction across substances from loci conferring risk for a specific drug. Individual common variants each contribute only a small increment of risk, so genetic vulnerability is best understood as an aggregate rather than as the effect of any identified gene.
Sources: en.wikipedia.org
Although IV and oral acetylcysteine are equally effective for this indication, oral administration is generally poorly tolerated due to the higher dosing required to overcome its low oral bioavailability, its foul taste and odor, and a higher incidence of adverse effects when taken orally, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine. Oral acetylcysteine is identical in bioavailability to cysteine precursors. However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting. Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people. Several studies have found this anaphylaxis-like reaction to occur more often in people given intravenous acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic.
== Research == Alfatradiol administered systemically improved metabolic function, reduced insulin resistance, decreased intra-abdominal fat, and decreased inflammation in old male mice without inducing feminization, suggesting potential usefulness in the treatment of type 2 diabetes.
=== Changes that occur during the onset of gingivitis and periodontitis and its role in bleeding on probing === Following the infiltration of bacteria and its products within the sulcular epithelium, the inflammatory response triggers the release of matrix metalloproteinases which cause collagen destruction. Studies suggest that this mechanism is through the activation of Toll-Like Receptors (TLRs, such as TLR-9) which are present on epithelial cells upon binding with bacterial products (such as lipopolysaccharides, unmyelinated CpG motifs). The expression of these collagenolytic matrix metalloproteinases like MMP-13 and activated NF-κB subunit p65 (a type of transcription factor) was more commonly present in periodontitis tissue compared to gingivitis tissue, indicating that the extent of connective tissue destruction accelerates with the progression of the disease. As an effort to curb the incoming bacterial invasion, the basal cells of the sulcular epithelium, being triggered by the ongoing inflammation, proliferate in hopes to maintain an intact barrier against the bacteria and their products. Due to the ongoing inflammation, engorgement of vessels and vasodilation occurs at the underlying connective tissue of the sulcular epithelium. The concurrent destruction of the collagen will then result in the thinning or ulceration of the sulcular epithelium, making the engorged and more abundant blood capillaries more susceptible to rupture upon innocuous mechanical stimuli (such as those during toothbrushing, probing, flossing, eating).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.